Please select the option that best describes you:
In patients receiving adjuvant cemiplimab for high-risk cutaneous SCC, what is your standard surveillance strategy for detecting relapse?
For radiographic surveillance of non-head and neck CSCC, do you rely on CT C/A/P, PET/CT, or a combination of modalities? Are you ever incorporating ctDNA into surveillance?
Answer from: at Academic Institution
Clinically, I follow patients every 3–4 months for the first 2 years, then every 6 months through year 5, and annually thereafter. These visits include a full skin exam, careful assessment of the primary site and draining nodal basins, and review for any late or persistent immune-related ...
Sign In or Register to read more
Answer from: at Academic Institution
Surveillance for those on adjuvant cemiplimab involves regular history and physical examinations, along with periodic radiologic examinations. Physical examinations are every 3-6 months, though in this very high-risk cohort, every 3 months is preferred. These exams should include skin examinations, ...
Answer from: at Academic Institution
Ultrasound (US), Computed Tomography (CT), Positron Emission Tomography (PET), and Magnetic Resonance Imaging (MRI) are all options for radiographic surveillance of patients at very high risk for cSCC disease relapse. Understanding the clinical presentation, tumor histology, and patient factors can ...